Myriad Genetics, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Myriad Genetics reported an adjusted loss of 11 cents per share for the quarter ended September 30, compared with breakeven a year earlier and analyst expectations of a 20-cent loss. Revenue fell 1.5% to $202.70 million, above analysts’ $191.33 million estimate; the company also reported a $43.9 million quarterly loss.

Confirmed

Global impact / market context

Revenue declined year over year, but exceeded analysts’ forecast, while the adjusted per-share loss was smaller than expected. That combination may affect investor views of near-term sales and cost control, though the reported quarterly loss and falling analyst earnings estimates point to continued pressure on profitability expectations.

Analyst inference

Analysts’ average rating was hold, with six holds, one buy or strong buy, and two sells or strong sells. Their median 12-month price target was $4.60, below the stated closing price of $6.04; these figures describe expectations, not guaranteed future performance.

Confirmed

What to watch

1. Future quarterly reports can show whether revenue stabilizes or continues falling; sustained declines could reduce sales available to cover operating costs and hinder a return to profitability. Analyst inference
2. Watch adjusted and reported losses together: adjusted earnings exclude selected items, while the reported loss reflects the company’s overall accounting result for the quarter. Analyst inference
3. Analysts’ earnings estimates had fallen about 23.2% over three months, and one analyst cut an estimate in the past 30 days; further changes could signal shifting profit expectations. Confirmed

Evidence

• Original source link unavailable